scholarly journals Profile of Hepatitis B Sero Markers Among Blood Donors Attending Usmanu Danfodiyo University Teaching Hospital, Sokoto-Nigeria

2021 ◽  
Vol 2 (5) ◽  
pp. 412-417
Author(s):  
Hussaini Mohammed Alhassan ◽  
Saudetu Haruna Shinkafi ◽  
Ibrahim Yakubu ◽  
Hamisu Abdullahi ◽  
Ahmad Hamidu Marafa ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Blood Donors ◽  
Adult Population ◽  
Age Groups ◽  
Sub Saharan Africa ◽  
University Teaching ◽  
B Virus ◽  
Test Component ◽  
Sub Saharan

Introduction: Hepatitis B Virus (HBV) is a double-stranded circular DNA virus, it is one of the major blood transmissible infections. The prevalence of HBV is highest in sub-Saharan Africa and East Asia, where 5-20% of the adult population are infected. In Africa, up to 15 to 60% of the population are positive for at least one of the serological markers of HBV. This study aimed to determine the prevalence markers of HBV among prospective blood donors in Sokoto. Materials/methods: About 170 blood donors were randomly recruited into this research study and 5ml of blood was aseptically collected from each of the research participants, the sample was screened for Hepatitis B virus, using a rapid step-wise HBV-5 panel immunoassay of Combo Cassette Manufactured by Lusys Laboratories Inc U.S.A. The HBV-5 is capable of detecting HBsAg, HBsAb, HBeAg, HBeAb and HBcAb simultaneously. The test component was opened from the notch, and the device was removed, 2-3 drops (60-90µl) plasma sample was added into the sample wells in the device. The result was read within 15 minutes. Results: The prevalence rates of the markers are HBsAg 8(4.7%), HBeAg 1(0.6%), HBsAb 7(4.1%), HbeAb 8(4.7%), and HBcAb 9(5.3%). Donors aged (20-30) years had the highest prevalence rate of HBV infection compared to other age groups. Male blood donors had higher seropositivity for the five markers than their female counterpart. The prevalence of HBV markers was high among the First time donors (non-vaccinated donors) who have a higher prevalence than other donors (vaccinated donors). Conclusion: This study has shown that screening for HBsAg alone may not be sufficient for the diagnosis of hepatitis B virus infection, and thus other markers should be included in the routine screening.

The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana

Blood ◽  
2003 ◽  
Vol 101 (6) ◽  
pp. 2419-2425 ◽  
Author(s):  
Jean-Pierre Allain ◽  
Daniel Candotti ◽  
Kate Soldan ◽  
Francis Sarkodie ◽  
Bruce Phelps ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Blood Donors ◽  
Hepatitis B Surface Antigen ◽  
Hbv Dna ◽  
Hbv Infection ◽  
Sub Saharan Africa ◽  
B Virus ◽  
Sub Saharan ◽  
Hbv Transmission

The risk of hepatitis B virus (HBV) transmission by transfusion in sub-Saharan Africa is considered to be relatively low, and testing of blood donors is often not done or is done relatively poorly. To re-examine this attitude, we identified HBV chronically infected blood donors from a major hospital in Ghana with a range of hepatitis B surface antigen (HBsAg) assays. Test efficacy was estimated using HBV DNA as a gold standard, and the risk of HBV infection in blood recipients was estimated for different testing strategies. Particle agglutination, dipstick, and enzyme immunoassay (EIA) HBsAg screening detected 54%, 71%, and 97% of HBV infectious donors, respectively. The risk of HBV transmission to recipients less than 10 years old ranged between 1:11 and 1:326 with blood unscreened and screened by EIA, respectively. For older recipients, the risk decreased a further 4-fold because of the high frequency of natural exposure to HBV. A total of 98% of HBsAg-confirmed positive samples contained HBV DNA. HBV DNA load was less than 1 × 104 IU/mL in 75% of HBsAg-reactive samples, most of them anti-HBe reactive. Approximately 0.5% of HBsAg-negative but anti-HBc-positive samples contained HBV DNA. The use of sensitive HBsAg tests is critical to prevent transfusion transmission of HBV infection to young children in a population with a 15% prevalence of chronic HBV infection in blood donors. However, this will not have much effect on the prevalence of this infection unless other strategies to protect children from infection are also advanced in parallel.

Untreated highly viraemic pregnant women from Asia or sub-Saharan Africa often transmit hepatitis B virus despite serovaccination to newborns

2014 ◽  
Vol 35 (2) ◽  
pp. 409-416 ◽  
Author(s):  
Pierre Sellier ◽  
Sarah Maylin ◽  
Rishma Amarsy ◽  
Marie-Christine Mazeron ◽  
Lucile Larrouy ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Sub Saharan Africa ◽  
B Virus ◽  
Sub Saharan

Hepatitis B virus activity in untreated hepatitis B e antigen–negative human immunodeficiency virus–hepatitis B virus co-infected patients from sub-Saharan Africa

2019 ◽  
Vol 113 (8) ◽  
pp. 437-445
Author(s):  
Anders Boyd ◽  
Menan Gerard Kouamé ◽  
Laura Houghtaling ◽  
Raoul Moh ◽  
Delphine Gabillard ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Sub Saharan Africa ◽  
Hepatitis B E Antigen ◽  
Hiv Rna ◽  
B Virus ◽  
Immunodeficiency Virus ◽  
Sub Saharan

Abstract Background In human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients from sub-Saharan Africa with hepatitis B e antigen (HBeAg)-negative status, data are limited on the evolution of HBV activity when antiretroviral treatment (ART) is absent. Methods A total of 43 HBeAg-negative co-infected patients not indicated for ART (per concomitant World Health Organization recommendations) were followed during participation in a randomized controlled trial in Côte d’Ivoire. Chronic HBeAg-negative phases were classified at yearly visits and defined as ‘infection’ (HBV DNA ≤10 000 copies/mL and normal alanine aminotransferase [ALT]) or ‘hepatitis’ (HBV DNA >10 000 copies/mL and/or above normal ALT). Dispersion in HBV DNA and ALT levels during follow-up was assessed using interquartile range (IQR) regression. Results During a median 25 months (IQR 19–31), 17 (40%) patients consistently had ‘infection’, 5 (12%) consistently had ‘hepatitis’ and 21 (48%) fluctuated between phases. Wider dispersion in HBV DNA over time was associated with higher baseline HIV RNA (p=0.02) and higher baseline HBV DNA levels (p=0.008), while wider dispersion in ALT was associated with higher baseline HIV RNA (p<0.001), higher baseline ALT levels (p=0.02) and baseline hepatitis surface antigen >4.0 log10 IU/mL (p=0.02). Conclusions HBV activity is common with HBeAg-negative status, whose variation is partly linked to HIV replication. Fluctuations in disease phase make it difficult to assess the risk of morbidity and mortality after ART initiation.

scholarly journals Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa

2017 ◽  
Vol 17 (S1) ◽  
Author(s):  
Patrick A. Coffie ◽  
◽  
Matthias Egger ◽  
Michael J. Vinikoor ◽  
Marcel Zannou ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Sub Saharan Africa ◽  
B Virus ◽  
Testing Practices ◽  
Sub Saharan ◽  
Virus Testing

scholarly journals Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areasr

1996 ◽  
Vol 117 (2) ◽  
pp. 313-325 ◽  
Author(s):  
W. J. Edmunds ◽  
G. F. Medley ◽  
D. J. Nokes ◽  
C. J. O'Callaghan ◽  
H. C. Whittle ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
East Asia ◽  
Horizontal Transmission ◽  
Perinatal Transmission ◽  
Sub Saharan Africa ◽  
B Virus ◽  
Age Dependent ◽  
Endemic Areas ◽  
Sub Saharan

SummaryThis paper uses meta-analysis of published data and a deterministic mathematical model of hepatitis B virus (HBV) transmission to describe the patterns of HBV infection in high endemicity areas. We describe the association between the prevalence of carriers and a simple measure of the rate of infection, the age at which half the population have been infected (A50), and assess the contribution of horizontal and perinatal transmission to this association. We found that the two main hyper-endemic areas of sub-Saharan Africa and east Asia have similar prevalences of carriers and values of A50, and that there is a negative nonlinear relationship between A50 and the prevalence of carriers in high endemicity areas (Spearman's Rank, P = 0·0086). We quantified the risk of perinatal transmission and the age-dependent rate of infection to allow a comparison between the main hyper-endemic areas. East Asia was found to have higher prevalences of HBeAg positive mothers and a greater risk of perinatal transmission from HBeAg positive mothers than sub-Saharan Africa, though the differences were not statistically significant. However, the two areas have similar magnitudes and age-dependent rates of horizontal transmission. Results of a simple compartmental model suggest that similar rates of horizontal transmission are sufficient to generate the similar patterns between A50 and the prevalences of carriers. Interrupting horizontal transmission by mass immunization is expected to have a significant, nonlinear impact on the rate of acquisition of new carriers.

scholarly journals Phylogeny of African complete genomes reveals a West African genotype A subtype of hepatitis B virus and relatedness between Somali and Asian A1 sequences

2005 ◽  
Vol 86 (8) ◽  
pp. 2163-2167 ◽  
Author(s):  
Charles Hannoun ◽  
Ann Söderström ◽  
Gunnar Norkrans ◽  
Magnus Lindh
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
West African ◽  
Sub Saharan Africa ◽  
Start Codon ◽  
Southern Asia ◽  
B Virus ◽  
Complete Genomes ◽  
Sub Saharan ◽  
Genotype A

Hepatitis B virus (HBV) is a major cause worldwide of liver disease, including hepatocellular carcinoma. There are eight known genotypes (A–H), of which genotype A has been divided into two subtypes: A2, prevalent in Europe, and A1, which is prevalent in sub-Saharan Africa, but also occurs in southern Asia. In this study, which includes 14 new complete genomes of non-European genotype A HBV, it was found that West African strains seem to constitute a new subgroup, A3. The high degree of genetic diversity within Africa indicates that genotype A originates from Africa. Based on a 2 % genetic distance between Asian and Somali sequences, it seems that the A1 subtype has spread from East Africa to southern Asia during the last 1000–2000 years. Moreover, it is proposed here that the A2 subtype originates from southern Africa and was imported to Europe around 500 years ago or later. The finding of T-1809/1812 close to the precore start codon and T-1862 and A-1888 in the precore region in HBV e antigen-positive children with signs of a mimimal immune response indicates that these substitutions are stable variants, rather than mutations emerging during infection in individual carriers.

scholarly journals Hepatitis B Vaccine Uptake among Voluntary Blood Donors in Jos: Implication on Blood Safety

2021 ◽  
Vol 2 (1) ◽  
pp. 35-41
Author(s):  
A Zakari ◽  
ED Jatau ◽  
VT Ma'an ◽  
ME Rumji ◽  
OD Damulak ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Blood Donors ◽  
Universal Access ◽  
Vaccine Uptake ◽  
Sub Saharan Africa ◽  
Blood Safety ◽  
Hbv Vaccine ◽  
Increased Risk ◽  
B Virus

Hepatitis B virus (HBV) is a transfusion-transmissible pathogen that poses a significant threat to blood safety. The virus' burden is high in the general population and among blood donors in Sub-Saharan Africa, leading to more donor rejection; blood discards, and increased risk of contamination of the blood supply. Hepatitis B Virus is vaccine-preventable; increased burden of infection may suggest a gap in vaccination. The study aimed to assess the level of hepatitis B virus vaccine uptake and identify factors affecting uptake of the vaccine among voluntary non remunerated blood donors (VNRBD) in Jos, Nigeria. A survey was conducted at the National Blood Transfusion Service (NBTS), Jos, among consenting VNRBD aged between 18 and 65 years from October to December 2020 using a structured questionnaire to collect information on vaccination status, socio-demographics and others. Of the 120 VNRBD interviewed, 36.7% received one or more doses of the HBV vaccine, while the majority (63.3%) were unvaccinated. Among the unvaccinated donors, 57.9% were unaware that HBV has a vaccine, 21.1% did not know where to get the vaccine, 7.9% had no time to get vaccinated; 3.9 % believed that there was no need to get vaccinated because they tested negative for the virus, while 9.2% gave no reason. Our study found a low uptake of HBV vaccine among VNRBD in our environment. We advocate for increased awareness and strong legislation to ensure universal access to the vaccine by Nigerians.

Sign in / Sign up

Export Citation Format

Share Document